AKT1 and acute myeloid leukemia: This finding could be relevant for treatment selection and personalized therapeutic approaches in AML as it implies that high-risk patients may be more sensitive to specific antitumor drugs, which targeted to PI3K–AKT–mTOR signaling pathways.